NewAmsterdam Pharma Company N.V. Ordinary Shares - Asset Resilience Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has an Asset Resilience Ratio of 20.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NAMS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NAMS total assets.
Liquid Assets Composition Over Time
This chart breaks down NewAmsterdam Pharma Company N.V. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of NewAmsterdam Pharma Company N.V. Ordinar to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $164.54 Million | 20.92% |
| Total Liquid Assets | $164.54 Million | 20.92% |
Asset Resilience Insights
- Good Liquidity Position: NewAmsterdam Pharma Company N.V. Ordinary Shares maintains a healthy 20.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
NewAmsterdam Pharma Company N.V. Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare NewAmsterdam Pharma Company N.V. Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares (2023–2024)
The table below shows the annual Asset Resilience Ratio data for NewAmsterdam Pharma Company N.V. Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.22% | $62.45 Million | $864.62 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $347.10 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more